What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors?

What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors?

What is the principal take-away from the LEADER trial about the role of liraglutide in patients with T2D and CV risk factors?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario